________________________________________________________________________________________________________________________
our commercial footprint there as our client base grows. Our Bedford site can produce pre-clinical, phase I and Phase II material for clinical trials, but we just lacked that commercial production capability because of the rigor associated with commercial versus clinical activities that the site wasn’ t yet set up for. As we looked to bring that capability to the US, it made good economic sense to purchase a facility that was already FDA approved and could facilitate clients’ speed to commercialization much faster.”
The new site in reference is in Durham, North Carolina and, in conjunction with OXB’ s Bedford site, takes the company’ s square footage in the country to a combined 217,000, with Bedford now focused on process development and Durham focused on GMP Manufacturing. The new Durham facility encompasses two state-of-the-art vector substance suites, and one vector product suite, with a further expansion-ready GMP suite. This expansion is representative
DATA DRIVEN GMP. MEANINGFUL IMPACT.
d2c-lifescience. com
CONTACT US:(+ 33) 3 88 81 87 52 contact @ d2c-lifescience. com
44